Evidence map›Paper›PMID 40687809›Full record

ArticleiScience2025

Biomedical engineering and interdisciplinary research in shaping tomorrow's medicine.

Angela Chen, Carly Harris, Cheng-Kui Qu

Abstract readNews
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Angela ChenDepartment of Pediatrics, Emory University School of Medicine, Aflac Cancer & Blood Disorders Center, Winship Cancer Institute, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Carly HarrisDepartment of Pediatrics, Emory University School of Medicine, Aflac Cancer & Blood Disorders Center, Winship Cancer Institute, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Cheng-Kui QuDepartment of Pediatrics, Emory University School of Medicine, Aflac Cancer & Blood Disorders Center, Winship Cancer Institute, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

Funding

Germline mutations of PTPN11 (SHP2) in the stem cell microenvironmentR01HL130995 · NHLBI · EMORY UNIVERSITY · PI QU, CHENG-KUI · 2016 to 2024
$3.3M
Metabolic regulation of stem cell niche development and functionR01HL162725 · NHLBI · EMORY UNIVERSITY · PI QU, CHENG-KUI · 2022 to 2025
$2.0M
Targeting leukemic stem cells in acute myeloid leukemiaR01CA275964 · NCI · EMORY UNIVERSITY · PI CHENG-KUI QU · 2023 to 2026
$1.7M
Eradicating leukemic stem cells in juvenile myelomonocytic leukemiaR21CA282579 · NCI · EMORY UNIVERSITY · PI QU, CHENG-KUI · 2023 to 2024
$391k
NCI NIH HHS R01 CA275964NCI NIH HHS R21 CA282579NHLBI NIH HHS R01 HL130995NHLBI NIH HHS R01 HL162725
6 · The paper itself

Abstract

Dr. Wilbur Lam merges pediatrics, biomedical engineering (BME), and innovation to advance patient care through interdisciplinary research. From developing a non-invasive smartphone app for anemia patients to leading national COVID-19 diagnostic efforts, Dr. Lam exemplifies how interdisciplinary collaboration can transform patient care. Blending passion, practicality, and scientific creativity, Dr. Lam inspires the next generation to bridge diverse fields in pursuit of accessible, life-changing medical solutions. His work sets a new standard for translational research and innovation in medicine.

Identifiers

PMID40687809
PMCPMC12271602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.